Blocking α4ß7 integrin binding to SIV does not improve virologic control.
Science
; 365(6457): 1033-1036, 2019 09 06.
Article
en En
| MEDLINE
| ID: mdl-31488690
ABSTRACT
A study in nonhuman primates reported that infusions of an antibody against α4ß7 integrin, in combination with antiretroviral therapy, showed consistent, durable control of simian immunodeficiency virus (SIV) in rhesus macaques. The antibody used has pleiotropic effects, so we set out to gain insight into the underlying mechanism by comparing this treatment to treatment with non-neutralizing monoclonal antibodies against the SIV envelope glycoprotein that only block α4ß7 binding to SIV Env but have no other host-directed effects. Similar to the initial study, we used an attenuated strain of SIV containing a stop codon in nef. The study used 30 macaques that all began antiretroviral therapy and then were divided into five groups to receive different antibody treatments. Unlike the published report, we found no sustained virologic control by these treatments in vivo.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Síndrome de Inmunodeficiencia Adquirida del Simio
/
Virus de la Inmunodeficiencia de los Simios
/
Integrina alfa4
/
Cadenas beta de Integrinas
/
Anticuerpos Monoclonales
/
Anticuerpos Antivirales
Límite:
Animals
Idioma:
En
Revista:
Science
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos